[1] Zappa C, Mousa S A. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016, 5(3): 288-300.
[2] Rakaee M, Busund L T, Paulsen E E, et al. Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer. Oncotarget. 2016, 7(44): 72184-72196.
[3] Aguiar Jr P N, De Mello R A, Hall P, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017, 9(6): 499-506.
[4] O’Keeffe L M, Taylor G, Huxley R R, et al. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018, 8(10): e021611.
[5] Hung R J, Spitz M R, Houlston R S, et al. Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15. 33 TERT-CLPTM1Ll Region. J Thorac Oncol. 2019, 14(8): 1360-1369.
[6] Malhotra J, Malvezzi M, Negri E, et al. Risk factors for lung cancer worldwide. Eur Respir J. 2016, 48(3): 889-902.
[7] Kadara H, Scheet P, Wistuba I I, et al. Early events in the molecular pathogenesis of lung cancer. Cancer Prev Res (Phila). 2016, 9(7): 518-527.
[8] Wood S L, Pernemalm M, Crosbie P A, et al. Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev. 2015, 41(4): 361-375.
[9] Kamphorst A O, Pillai R N, Yang S, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017, 114(19): 4993-4998.
[10] Barr Kumarakulasinghe N, Zanwijk N, Soo R A. Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer (NSCLC). Respirology. 2015, 20(3): 370-378.
[11] Schmitt A M, Chang H Y. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016, 29(4): 452-463.
[12] Evans J R, Feng F Y, Chinnaiyan A M. The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 2016, 126(8): 2775-2782.
[13] Khorkova O, Hsiao J, Wahlestedt C. Basic biology and therapeutic implications of lncRNA. Adv Drug Deliv Rev. 2015, 87: 15-24.
[14] Lan T, Yuan K, Yan X, et al. LncRNA SNHG10 facilitates hepatocarcinogenesis and metastasis by modulating its homolog SCARNA13 via a positive feedback loop. Cancer Res. 2019, 79(13): 3220-3234.
[15] Pfeffer S R, Yang C H, Pfeffer L M. The role of miR-21 in cancer. Drug Dev Res. 2015, 76(6): 270-277.
[16] Mao Z, Li H, Du, B, et al. LncRNA DANCR promotes migration and invasion through suppression of lncRNA-LET in gastric cancer cells. Bioscience reports, 2017, 37(6): BSR20171070.
[17] Wei W, Liu Y, Lu Y, et al. LncRNA XIST promotes pancreatic cancer proliferation through miR‐133a/EGFR. Journal of cellular Biochemistry, 2017, 118(10): 3349-3358.
[18] Antonia S J, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018, 379(24): 2342-2350.
[19] Alvarez J G B, González-Cao M, Karachaliou N, et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med. 2015, 12(3): 209-222.
[20] Park S, Eom K, Kim J, et al. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. BMC cancer, 2017, 17(1): 658.
[21] Han J G, Jiang Y D, Zhang C H, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Annals of surgical treatment and research, 2017, 92(2): 55-66.
[22] Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. Journal of Experimental & Clinical Cancer Research, 2017, 36(1): 53.
[23] Xue X, Liu Y, Wang Y, et al. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget, 2016, 7(51): 84508.
[24] Wang P, Chen D, Ma H, et al. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. OncoTargets and therapy, 2017, 10: 5137.
[25] Zhang H, Mao F, Shen T, et al. Plasma miR‑145, miR‑20a, miR‑21 and miR‑223 as novel biomarkers for screening early‑stage non‑small cell lung cancer. Oncology letters, 2017, 13(2): 669-676.